Cerebrovascular Diseases
Original Paper
Utility of the Kurashiki Prehospital Stroke Scale for Hyperacute StrokeIguchi Y. · Kimura K. · Watanabe M. · Shibazaki K. · Aoki J.Department of Stroke Medicine, Kawasaki Medical School, Kurashiki-City, Japan
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: April 27, 2010
Accepted: August 20, 2010
Published online: October 28, 2010
Issue release date: December 2010
Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 4
ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)
For additional information: https://www.karger.com/CED
Abstract
Backgrounds: Our aim was to confirm the utility of paramedics using the Kurashiki Prehospital Stroke Scale (KPSS), with a maximum score of 13, for patients who may be eligible for administration of intravenous tissue plasminogen activator (IV t-PA). Methods: The subjects comprised acute stroke and transient ischemic attack (TIA) patients transferred to our hospital by paramedics. We analyzed correlations between KPSS and the National Institutes of Health Stroke Scale (NIHSS). Patients admitted within 3 h of onset were categorized into 2 groups: KPSS ≧4 and KPSS <4. We compared the proportion of patients receiving IV t-PA between the groups. Results: Among 430 consecutive patients (mean age = 73 years; 266 men), paramedics recorded KPSS for 256 patients (59.5%). Excellent correlation was observed between KPSS and NIHSS in all 256 patients (R = 0.766; p < 0.001) and in 94 patients (ischemic stroke and TIA with symptoms on admission) admitted within 3 h of onset (R = 0.706; p < 0.001). Among these 94 patients, IV t-PA was more frequently given in the KPSS ≧4 group (30 of 58 patients, 51.7%) than in the KPSS <4 group (5 of 36 patients, 13.9%; p < 0.001). Arterial occlusion was more frequently observed in the KPSS ≧4 group (57.9 vs. 31.4%, p = 0.018). KPSS ≧4 was independently associated with administration of IV t-PA (odds ratio = 4.7; 95% confidence interval = 1.5–14.6, p = 0.008). Conclusion: Reliable concordance between KPSS and NIHSS was found in acute stroke and TIA patients. KPSS ≧4 represents a good score to indicate prospective t-PA patients among those admitted within 3 h of stroke onset.
© 2010 S. Karger AG, Basel
Related Articles:
References
- The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587.
- Schroeder EB, Rosamond WD, Morris DL, Evenson KR, Hinn AR: Determinants of use of emergency medical services in a population with stroke symptoms: the second delay in accessing stroke healthcare (DASH II) study. Stroke 2000;31:2591–2596.
- Iguchi Y, Wada K, Shibazaki K, Inoue T, Ueno Y, Yamashita S, Kimura K: First impression at stroke onset plays an important role in early hospital arrival. Intern Med 2006;45:447–451.
- Kidwell CS, Starkman S, Eckstein M, Weems K, Saver JL: Identifying stroke in the field: prospective validation of the Los Angeles Prehospital Stroke Screen (LAPSS). Stroke 2000;31:71–76.
- Kothari RU, Pancioli A, Liu T, Brott T, Broderick J: Cincinnati prehospital stroke scale: reproducibility and validity. Ann Emerg Med 1999;33:373–378.
- Kimura K, Inoue T, Iguchi Y, Shibazaki K: Kurashiki prehospital stroke scale. Cerebrovasc Dis 2008;25:189–191.
- Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, Shinohara Y; J-ACT Group: Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset – Japan Alteplase Clinical Trial (J-ACT). Stroke 2006;37:1810–1815.
- Tirschwell DL, Longstreth WT Jr, Becker KJ, Gammans RE Sr, Sabounjian LA, Hamilton S, Morgenstern LB: Shortening the NIH stroke scale for use in the prehospital setting. Stroke 2002;33:2801–2806.
- Bray JE, Martin J, Cooper G, Barger B, Bernard S, Bladin C: Paramedic identification of stroke: community validation of the Melbourne ambulance stroke screen. Cerebrovasc Dis 2005;20:28–33.
- Alberts MJ, Latchaw RE, Selman WR, Shephard T, Hadley MN, Brass LM, Koroshetz W, Marler JR, Booss J, Zorowitz RD, Croft JB, Magnis E, Mulligan D, Jagoda A, O’Connor R, Cawley CM, Connors JJ, Rose-DeRenzy JA, Emr M, Warren M, Walker MD: Recommendations for comprehensive stroke centers: a consensus statement from the brain attack coalition. Stroke 2005;36:1597–1616.
- Iguchi Y, Kimura K, Shibazaki K, Iwanaga T: Increasing number of stroke specialists should contribute to utilization of IV rt-PA: results of questionnaires from 1466 hospitals in Japan. J Neurol Sci 2009;279:66–69.
Article / Publication Details
Received: April 27, 2010
Accepted: August 20, 2010
Published online: October 28, 2010
Issue release date: December 2010
Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 4
ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)
For additional information: https://www.karger.com/CED
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
